TriNetX
  • Life Sciences
  • Healthcare
  • Data
    • Exploring RWD
    • Ethics Hotline
    • Trust Center
  • Products
    • EVIDEX® Drug Safety Platform
      • EVIDEX® Drug Safety
      • EVIDEX® Signal Detection
      • EVIDEX® Advanced Analytics
      • EVIDEX® Signal Management
      • EVIDEX® Support
      • Log in to EVIDEX®
    • TriNetX Platform
      • Networks
        • LIVE Regional Networks
        • Linked Claims Network
        • Japan Claims Network
      • Features
        • Query Builder
        • TriNetX Connect
        • Base Analytics
        • Advanced Analytics
        • Follow the Patient
        • Bring Your Own Model
        • LUCID – Trusted Research Environment
        • Diversity Lens
    • TriNetX Data Sets
      • Curated Oncology
      • Linked Claims & EHR
      • Dataworks Enriched EHR
      • Open Claims
      • KOL Activity Reports
      • Bring Your Own Data
  • Services
    • Protocol feasibility and site identification
    • Chart Review
    • HEOR
    • Publications and Abstracts
    • Data Set Curation
    • Staff Augmentation
  • Resources
    • Webinars and Events
    • Publications
    • PV Library
      • All PV resources
      • GVP Module IX for Signal Management: The Complete Guide
      • Pharmacovigilance Signal Detection: The Complete Guide
    • Case Studies
    • Blog
    • Press Releases
    • Coronavirus
  • About Us
    • Leadership
    • Board of Directors
    • Community
    • Careers
    • Contact Us
  • Connect With Us
  • Sign In
Select Page
TriNetX-enabled research drives learning at ASH 2022

TriNetX-enabled research drives learning at ASH 2022

Jan 6, 2023 | Blog, Events, News, Published Research

In December, a contingent of our real-world data experts attended the 2022 Annual Meeting of the American Society of Hematology. Led by Chief Scientific Officer Jeffrey Brown and Senior Vice President, TriNetX Oncology GmbH Lenka Kellerman, our team spent their time...

Journal of Clinical Hypertension – “First‐line treatment of essential hypertension: A real‐world analysis across four antihypertensive treatment classes”

Apr 13, 2019 | Published Research

This study was written by Manfred Stapff, MD, PhD, Chief Medical Officer at TriNetX, and Sarah Hilderbrand, MSc and published in the Journal of Clinical Hypertension describing how electronic medical records can be used to analyze and compare actual treatment...

World Journal of Diabetes – “Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes”

Dec 15, 2018 | Published Research

This study published in the World Journal of Diabetes evaluates the effect on cardiovascular outcomes of sodium-glucose co-transporter-2 (SGLT2) inhibitors in a real world setting by analyzing electronic medical records.Manfred Paul Stapff, CMO, TriNetX Inc.,...

ISPOR Europe 2018 – Parkinson’s Disease Study

Nov 12, 2018 | Published Research

This scientific poster investigates the risk of Parkinson’s Disease (PD) in patients taking adrenergic drug treatments. Download the poster...

ISPOR Europe 2018 – Suicidality Study

Nov 12, 2018 | Published Research

This scientific poster is comparing the risk of suicidality in adult versus youth patients treated with serotonin reuptake inhibitors—A real-world evidence-based approach. Download the poster...

ISPOR Europe 2018 – Chronic Kidney Disease Study

Nov 12, 2018 | Published Research

This scientific poster investigates the risk of stroke or systemic embolism in chronic kidney disease patients with atrial fibrillation. Download the poster...
« Older Entries

TriNetX, LLC complies with all applicable privacy laws. For more information please visit our Trust Center.

ABOUT TRINETX, LLC

TriNetX is the global health research network that connects the world of drug discovery and development from pharmaceutical company to study site, and investigator to patient by sharing real-world data to make clinical and observational research easier and more efficient. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to optimize protocol design and feasibility, site selection, patient recruitment, and enable discoveries through the generation of real-world evidence. The TriNetX platform is HIPAA and GDPR compliant. For more information, visit TriNetX at www.trinetx.com or follow @TriNetX on Twitter.

Terms of Use
Privacy & Cookies

SIGN UP TO RECEIVE TRINETX COMMUNICATIONS

  • Twitter
©2022 TriNetX, LLC All Rights Reserved.